血漿プロテアーゼC1阻害剤の市場規模、シェア、動向分析レポート：薬剤クラス別、剤形別、流通チャネル別、地域別、セグメント別予測、2024年～2030年

血漿プロテアーゼC1阻害剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、血漿プロテアーゼC1阻害剤の世界市場規模は、2024～2030年にかけてCAGR 9.79%で拡大し、2030年には62億1,000万米ドルに達すると予測されています。

血漿プロテアーゼC1阻害剤の世界市場は、希少な遺伝性疾患である遺伝性血管性浮腫（HAE）の発生率が上昇し、C1阻害剤のような効果的な治療への需要が高まっているなど、複数の極めて重要な要因によって推進されています。さらに、バイオテクノロジーの進歩は生産効率を向上させ、これらの療法をより利用しやすくしています。

HAEと関連疾患に対する認識の高まりと診断の改善は、さらに市場の大幅な成長に寄与しています。HAEは世界中で約5万人に1人の割合で発症しており、症状を緩和し患者のQOLを改善する治療法の緊急の必要性を強調しています。さらに、バイオテクノロジーの進歩により、遺伝子組換え製品の開発が可能になり、世界中の患者にとってより高い有効性と利用しやすさが約束されるようになりました。これらの推進力は、C1-INH業界の情勢を形成する上で極めて重要であり、新たな治療オプションの採用と投資の拡大を促進しています。

治療における技術革新は、様々な症状における治療基準を再定義することになります。例えば、長時間作用型製剤の採用は、治療効果を延長し、治療頻度を減らし、患者のコンプライアンスを向上させます。さらに、抗体媒介性自己免疫疾患など、HAE以外の新たな適応症に関する進行中の調査は、アンメットメディカルニーズへの対応における治療法の多様性と可能性を示しています。これらの進歩は、治療用途の拡大と患者の転帰の最適化を目指した絶え間ない研究開発努力に後押しされた、この業界のダイナミックな性質を強調するものです。

業界は拡大を続けており、市場関係者は主要課題への対応と成長機会の獲得にますます注力しています。規制の進展と有利な償還政策が市場の拡大をさらに促進し、世界中の患者がC1-INH療法をより利用しやすくなると予想されています。市場開拓企業は、こうした規制の進展を活用して業界参入プロセスを合理化し、革新的治療へのタイムリーなアクセスを確保しています。CSLベーリングや武田薬品工業などの企業は、需要の高まりに対応し、世界のサプライチェーンの強靭性を確保するため、生産能力の拡大に積極的に投資しています。さらに、研究機関や規制当局とのパートナーシップにより、イノベーションを促進し、新たなC1-INH治療の承認プロセスを加速させています。このような積極的な取り組みは、治療の選択肢を増やし、市場でのリーダーシップを強化するというコミットメントを強調するものであり、利害関係者は、進化する医療の状況において持続的な成長と成功を収めることができます。

血漿プロテアーゼC1阻害剤市場レポートハイライト

• 薬剤クラス別では、C1阻害薬が市場を独占し、2023年に最大シェアを占める。選択的ブラジキニンB2受容体拮抗薬は、主要企業による研究開発イニシアチブの実施により、予測期間中に最も速い成長率で成長すると予測されます。
• 剤形別では、安定性、保存期間の長さ、保管・輸送の容易さから、血漿プロテアーゼC1阻害薬治療に好まれる凍結乾燥製剤が2023年に圧倒的なシェアを占め、患者と医療プロバイダーの双方にとって有効性と利便性が確保されています。
• 流通チャネル別では、病院薬局が2023年の市場を独占しています。その理由は、病院薬局が広く利用可能であること、規制を遵守していること、血漿プロテアーゼC1阻害剤のような特殊な療法を効果的に取り扱う能力があることです。
• 北米は、高い医療支出、高度な医療インフラ、堅実な調査、遺伝性血管性浮腫のような様々な希少疾患に対する血漿プロテアーゼC1阻害薬治療の大幅な採用により、市場を独占し、2023年に最大のシェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブ概要

第3章 血漿プロテアーゼC1阻害剤市場の変数、動向、範囲

• 血漿プロテアーゼC1阻害剤市場の系統展望
  • 親市場の展望
  • 補助市場の展望
• 市場力学
  • 市場ドライバー分析
  • 市場抑制要因分析
• 血漿プロテアーゼC1阻害剤市場分析ツール
  • ポーターのファイブフォース分析
  • PESTLE分析

第4章 血漿プロテアーゼC1阻害剤市場分析、薬剤クラス別、2018～2030年（100万米ドル）

• 薬剤クラス別市場シェア、2023年と2030年
• セグメントダッシュボード
• 血漿プロテアーゼC1阻害剤市場-薬剤クラス別展望
  • C1阻害薬
  • カリクレイン阻害剤
  • 選択的ブラジキニンB2受容体拮抗薬

第5章 血漿プロテアーゼC1阻害剤市場分析、剤形別、2018～2030年（100万米ドル）

• 剤形別市場シェア、2023年と2030年
• セグメントダッシュボード
• 血漿プロテアーゼC1阻害剤市場-剤形別展望
  • 凍結乾燥
  • 注射剤

第6章 血漿プロテアーゼC1阻害剤市場分析、流通チャネル別、2018～2030年（100万米ドル）

• 流通チャネル別市場シェア、2023年と2030年
• セグメントダッシュボード
• 血漿プロテアーゼC1阻害剤市場-流通チャネル別展望
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 血漿プロテアーゼC1阻害剤市場：薬剤クラス別、地域推定・動向分析

• 血漿プロテアーゼC1阻害剤市場：地域別展望
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 市場参入企業の分類
• 主要企業プロファイル
  • CSL
  • Takeda Pharmaceutical Company Limited
  • Pharming
  • KalVista Pharmaceuticals.
  • Sanquin
  • BioCryst Pharmaceuticals, Inc.
  • CENTOGENE NV

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global protease C1-inhibitor market, by region, 2018 - 2030 (USD Million)
• Table 4 Global plasma protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 5 Global plasma protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 6 Global plasma protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7 North America protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
• Table 8 North America protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 9 North America protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 10 North America protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11 U.S. protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 12 U.S. protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 13 U.S. protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 14 Canada protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 15 Canada protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 16 Canada protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17 Mexico protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 18 Mexico protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 19 Mexico protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20 Europe protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
• Table 21 Europe protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 22 Europe protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 23 Europe protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 Germany protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 25 Germany protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 26 Germany protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 27 UK protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 28 UK protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 29 UK protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30 France protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 31 France protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 32 France protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 33 Italy protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 34 Italy protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 35 Italy protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 36 Spain protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 37 Spain protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 38 Spain protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 39 Denmark protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 40 Denmark protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 41 Denmark protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42 Sweden protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 43 Sweden protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 44 Sweden protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 45 Norway protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 46 Norway protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 47 Norway protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52 China protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 53 China protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 54 China protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 55 Japan protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 56 Japan protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 57 Japan protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58 India protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 59 India protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 60 India protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 South Korea protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 62 South Korea protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 63 South Korea protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 64 Australia protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 65 Australia protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 66 Australia protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67 Thailand protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 68 Thailand protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 69 Thailand protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 70 Latin America protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
• Table 71 Latin America protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 72 Latin America protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 73 Latin America protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 74 Brazil protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 75 Brazil protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 76 Brazil protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 77 Argentina protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 78 Argentina protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 79 Argentina protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 80 MEA protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
• Table 81 MEA protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 82 MEA protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 83 MEA protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 84 South Africa protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 85 South Africa protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 86 South Africa protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90 UAE protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 91 UAE protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 92 UAE protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
• Table 93 Kuwait protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
• Table 94 Kuwait protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
• Table 95 Kuwait protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Plasma protease C1-inhibitor market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Drug class and dosage form segment snapshot
• Fig. 11 Distribution channel segment snapshot
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Global Pharmaceutical Market, (USD billion)
• Fig. 14 Market dynamics
• Fig. 15 Porter's five forces analysis
• Fig. 16 PESTLE analysis
• Fig. 17 Plasma protease C1-inhibitor: Drug Class outlook and key takeaways
• Fig. 18 Plasma protease C1-inhibitor market: Drug Class market movement analysis
• Fig. 19 C1-inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 C1-esterase Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Recombinant Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Kallikrein Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Selective Bradykinin B2 Receptor Antagonist market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Plasma protease C1-inhibitor: Dosage form outlook and key takeaways
• Fig. 25 Plasma protease C1-inhibitor market: Dosage form market movement analysis
• Fig. 26 Lyphophlised market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Injectables market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Plasma protease C1-inhibitor: Distribution channel outlook and key takeaways
• Fig. 29 Plasma protease C1-inhibitor market Distribution channel market movement analysis
• Fig. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Plasma protease C1-inhibitor market revenue, by region, 2023 & 2030 (USD Million)
• Fig. 34 Regional marketplace: Key takeaways
• Fig. 35 Regional marketplace: Key takeaways
• Fig. 36 North America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Key country dynamics
• Fig. 38 US plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Key country dynamics
• Fig. 40 Canada plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Key country dynamics
• Fig. 42 Mexico plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Europe plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Key country dynamics
• Fig. 45 UK plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Key country dynamics
• Fig. 47 Germany plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Key country dynamics
• Fig. 49 France plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Key country dynamics
• Fig. 51 Spain plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Key country dynamics
• Fig. 53 Italy plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Key country dynamics
• Fig. 55 Denmark plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Key country dynamics
• Fig. 57 Sweden plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Key country dynamics
• Fig. 59 Norway plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Rest of Europe plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Asia Pacific plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Key country dynamics
• Fig. 63 Japan plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Key country dynamics
• Fig. 65 China plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 China regulatory details
• Fig. 67 India plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Key country dynamics
• Fig. 69 Australia plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Key country dynamics
• Fig. 71 Thailand plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Key country dynamics
• Fig. 73 South Korea plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 South Korea reimbursement scenario
• Fig. 75 Rest of Asia Pacific plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Latin America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Key country dynamics
• Fig. 78 Brazil plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Brazil regulation details
• Fig. 80 Brazil reimbursement scenario
• Fig. 81 Key country dynamics
• Fig. 82 Argentina plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Argentina regulatory framework
• Fig. 84 Rest of Latin America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Key country dynamics
• Fig. 86 South Africa plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Key country dynamics
• Fig. 88 Saudi Arabia plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Key country dynamics
• Fig. 90 UAE plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Key country dynamics
• Fig. 92 Kuwait plasma protease C1-inhibitor market estimates and forecasts, 2018
• Fig. 93 Rest of MEA plasma protease C1-inhibitor market estimates and forecasts,
• Fig. 94 Company/competition categorization
• Fig. 95 Company market share analysis, 2023
• Fig. 96 Strategy mapping

Plasma Protease C1-inhibitor Market Growth & Trends:

The global plasma protease C1-inhibitor market size is anticipated to reach USD 6.21 billion by 2030, expanding at a CAGR of 9.79% from 2024 to 2030, according to a new report by Grand View Research, Inc. The global market for plasma protease C1-inhibitor is propelled by multiple pivotal factors such as the rising incidence of hereditary angioedema (HAE), a rare genetic disorder, increases the demand for effective therapies such as C1-inhibitor. Furthermore, advancements in biotechnology improve production efficiency, making these therapies more accessible.

Increased awareness and improved diagnosis of HAE and related conditions further contribute to substantial market growth. HAE affects approximately 1 in 50,000 individuals worldwide, underscoring the urgent need for therapies to alleviate symptoms and improve patient quality of life. Furthermore, advancements in biotechnology have enabled the development of recombinant products, which promise enhanced efficacy and accessibility for patients globally. These drivers are pivotal in shaping the landscape of the C1-INH industry, facilitating greater adoption and investment in novel treatment options.

Innovations in therapies are set to redefine treatment standards across various conditions. For instance, the introduction of long-acting formulations offers extended therapeutic effects, reducing treatment frequency and improving patient compliance. Additionally, ongoing research into new indications beyond HAE, such as antibody-mediated autoimmune diseases, showcases the versatility and potential of therapies in addressing unmet medical needs. These advancements underscore the dynamic nature of the industry, driven by continuous research and development efforts aimed at expanding therapeutic applications and optimizing patient outcomes.

Industry continues to expand; market players are increasingly focused on addressing key challenges and seizing opportunities for growth. Regulatory advancements and favorable reimbursement policies are anticipated to further propel market expansion, facilitating greater accessibility to C1-INH therapies for patients globally. Market players are leveraging these regulatory developments to streamline industry entry processes and ensure timely access to innovative treatments. Companies such as CSL Behring and Takeda Pharmaceutical are actively investing in expanding production capacities to meet escalating demand and ensure global supply chain resilience. Moreover, partnerships with research institutions and regulatory bodies are fostering innovation and accelerating the approval process for new C1-INH therapies. These proactive measures underscore a commitment to advancing treatment options and reinforcing market leadership, positioning stakeholders for sustained growth and success in the evolving healthcare landscape.

Plasma Protease C1-inhibitor Market Report Highlights:

• Based on drug class, C1-inhibitors dominated the market and accounted for the largest share in 2023. Selective bradykinin B2 receptor antagonist anticipated to grow at the fastest growth rate over the forecast period owing to undergoing R&D initiatives being undertaken by major players
• Based on dosage form, the lyophilized segment held a dominant share in 2023 due to their stability, longer shelf life, and ease of storage and transportation, making them preferred for plasma protease C1-inhibitor therapies, ensuring efficacy and convenience for patients and healthcare providers alike
• Based on distribution channel, hospital pharmacies dominated the market in 2023 due to their widespread accessibility, regulatory compliance, and ability to handle specialized therapies like plasma protease C1-inhibitor effectively
• North America dominated the market and accounted for the largest share in 2023 owing to high healthcare spending, advanced healthcare infrastructure, robust research, and significant adoption of Plasma Protease C1-inhibitor therapies for various rare diseases like hereditary angioedema.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Dosage form
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Drug Class and Dosage Form Snapshot
• 2.3. Distribution Channel Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Plasma Protease C1-inhibitor Market Variables, Trends, and Scope

• 3.1. Plasma Protease C1-inhibitor Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Disease Awareness
    • 3.2.1.2. Advancements in Treatment Options
    • 3.2.1.3. Expansion of Indications
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost of Treatment
    • 3.2.2.2. Side Effects and Safety Concerns
    • 3.2.2.3. Regulatory Challenges
• 3.3. Plasma Protease C1-inhibitor Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTLE Analysis

Chapter 4. Plasma Protease C1-inhibitor Market Analysis, by Drug Class, 2018 - 2030 (USD Million)

• 4.1. Drug Class Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Plasma Protease C1-inhibitor Market by Drug Class Outlook
  • 4.3.1. C1-inhibitors
    • 4.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.2. C1-esterase Inhibitor
    • 4.3.1.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.3. Recombinant Inhibitor
    • 4.3.1.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Kallikrein Inhibitor
    • 4.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.3. Selective Bradykinin B2 Receptor Antagonist
    • 4.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Plasma Protease C1-inhibitor Market Analysis, by Dosage Form, 2018 - 2030 (USD Million)

• 5.1. Dosage Form Market share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Plasma Protease C1-inhibitor Market by Dosage Form Outlook
  • 5.3.1. Lyphophlised
    • 5.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. Injectables
    • 5.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Plasma Protease C1-inhibitor Market Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

• 6.1. Distribution Channel Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Plasma Protease C1-inhibitor Market by Distribution Channel Outlook
  • 6.3.1. Hospital Pharmacies
    • 6.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. Retail Pharmacies
    • 6.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.3. Online Pharmacies
    • 6.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Plasma Protease C1-inhibitor Market: Regional Estimates and Trend Analysis by Drug Class, by Dosage Form

• 7.1. Plasma Protease C1-inhibitor Market: Regional Outlook
• 7.2. North America
  • 7.2.1. North America Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. U.S. Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2.3. Competitive/Market Scenario
    • 7.2.2.4. Regulatory Framework
    • 7.2.2.5. Reimbursement scenario
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Canada Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3.3. Competitive/Market Scenario
    • 7.2.3.4. Regulatory Framework
    • 7.2.3.5. Reimbursement Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Mexico Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4.3. Competitive/Market Scenario
    • 7.2.4.4. Regulatory Framework
    • 7.2.4.5. Reimbursement Scenario
• 7.3. Europe
  • 7.3.1. Europe Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. UK Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2.3. Competitive/Market Scenario
    • 7.3.2.4. Regulatory Framework
    • 7.3.2.5. Reimbursement Scenario
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Germany Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3.3. Competitive/Market Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. Reimbursement Scenario
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. France Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4.3. Competitive/Market Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Reimbursement Scenario
  • 7.3.5. Spain
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Spain Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5.3. Competitive/Market Scenario
    • 7.3.5.4. Regulatory Framework
    • 7.3.5.5. Reimbursement Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Italy Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6.3. Competitive/Market Scenario
    • 7.3.6.4. Regulatory Framework
    • 7.3.6.5. Reimbursement Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Denmark Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7.3. Competitive/Market Scenario
    • 7.3.7.4. Regulatory Framework
    • 7.3.7.5. Reimbursement Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Sweden Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8.3. Competitive/Market Scenario
    • 7.3.8.4. Regulatory Framework
    • 7.3.8.5. Reimbursement Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Norway Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9.3. Competitive/Market Scenario
    • 7.3.9.4. Regulatory Framework
    • 7.3.9.5. Reimbursement Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Plasma Protease C1-inhibitor Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Japan Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2.3. Competitive/Market Scenario
    • 7.4.2.4. Regulatory Framework
    • 7.4.2.5. Reimbursement Scenario
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. China Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3.3. Competitive/Market Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. Reimbursement Scenario
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. India Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4.3. Competitive/Market Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. Reimbursement Scenario
  • 7.4.5. Australia
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Australia Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5.3. Competitive/Market Scenario
    • 7.4.5.4. Regulatory Framework
    • 7.4.5.5. Reimbursement Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Thailand Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6.3. Competitive/Market Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Reimbursement Scenario
  • 7.4.7. South Korea
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. South Korea Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7.3. Competitive/Market Scenario
    • 7.4.7.4. Regulatory Framework
    • 7.4.7.5. Reimbursement Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Brazil Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2.3. Competitive/Market Scenario
    • 7.5.2.4. Regulatory Framework
    • 7.5.2.5. Reimbursement Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Argentina Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3.3. Competitive/Market Scenario
    • 7.5.3.4. Regulatory Framework
    • 7.5.3.5. Reimbursement Scenario
• 7.6. MEA
  • 7.6.1. MEA Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. South Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2.3. Competitive/Market Scenario
    • 7.6.2.4. Regulatory Framework
    • 7.6.2.5. Reimbursement Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Saudi Arabia Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3.3. Competitive/Market Scenario
    • 7.6.3.4. Regulatory Framework
    • 7.6.3.5. Reimbursement Scenario
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. UAE Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4.3. Competitive/Market Scenario
    • 7.6.4.4. Regulatory Framework
    • 7.6.4.5. Reimbursement Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Kuwait Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5.3. Competitive/Market Scenario
    • 7.6.5.4. Regulatory Framework
    • 7.6.5.5. Reimbursement Scenario

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. CSL
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Takeda Pharmaceutical Company Limited
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Pharming
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. KalVista Pharmaceuticals.
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Sanquin
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. BioCryst Pharmaceuticals, Inc.
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. CENTOGENE N.V.
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives